BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Cancer Treatment Centers Of America Release: Jesus Esquivel, MD, FACS To Present At 67th Society For Surgical Oncology Annual Cancer Symposium


2/24/2014 9:34:38 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SCHAUMBURG, Ill., Feb. 24, 2014 /PRNewswire-USNewswire/ -- Jesus Esquivel, MD, FACS, National Director of HIPEC Research and Medical Director, International Oncology Initiatives for Cancer Treatment Centers of America, has been selected to make two oral presentations at the 67th Society for Surgical Oncology Annual Cancer Symposium, taking place March 12-15, 2014 in Phoenix, Arizona. The symposium is a leading international scientific meeting that offers attendees the opportunity to learn about the latest advances in surgical oncology.

Cancer Treatment Centers Of America logo.

Dr. Esquivel's presentations both involve the Peritoneal Surface Disease Severity Score (PSDSS) and its potential as diagnostic aide in evaluating treatment options. His first presentation, titled "Evaluation of a new staging classification and a PSDSS in 229 patients with mucinous appendiceal neoplasms with or without peritoneal dissemination", examines ways of using the PSDSS as a determinant of current therapies in patients with mucinous appendiceal neoplasms with or without peritoneal dissemination. The findings were significant in that, they indicate that the PSDSS may serve as an important prognostic indicator and that can improve the selection of patients to receive an appropriate therapy from the time of diagnosis.

Dr. Esquivel will also share his findings of his study titled "The American Society of Peritoneal Surface Malignancies (ASPSM) multi-institution evaluation of the PSDSS in 1,048 patients with colorectal cancer with Peritoneal Carcinomatosis." This study explored the theory that cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) may play an important role in the management of colorectal cancer patients with peritoneal carcinomatosis (CRCPC). The study results found that when a PSDSS score is determined prior to surgery it is capable of defining CRCPC populations who have a statistically-defined high or considerably lower likelihood of long-term survival following HIPEC. This finding implies that PSDSS can be useful in the decision to enter CRCPC patients into, and their stratification within, specific clinical trials.

"I am honored by the opportunity to present this research at the Society of Surgical Oncology's Cancer Symposium," said Dr. Esquivel. "Both of these studies represent- the collective efforts of a variety of surgical oncology experts with results that have direct practice implications and will effect patient's treatment options. We are excited about the effect that PSDSS can have in refining the diagnostic process and ultimately, assist in selecting the best treatment options for colorectal cancer patients."

About Cancer Treatment Centers of America®

Cancer Treatment Centers of America, Inc. (CTCA) is a national network of hospitals focusing on complex and advanced stage cancer. CTCA offers a comprehensive, fully integrative approach to cancer treatment and serves patients from all 50 states at facilities located in Atlanta, Chicago, Philadelphia, Phoenix and Tulsa. Known for delivering the Mother Standard® of care and Patient Empowerment Medicine®, CTCA provides patients with information about cancer and their treatment options so they can control their treatment decisions. For more information about CTCA, go to www.cancercenter.com.

Logo: http://photos.prnewswire.com/prnh/20090612/CTCALOGO

SOURCE Cancer Treatment Centers of America



Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES